02:37 PM EDT, 06/26/2025 (MT Newswires) -- Merck ( MRK ) said Thursday the US Centers for Disease Control and Prevention's committee recommended Enflonsia as a preventive option for respiratory syncytial virus lower respiratory tract disease in infants aged under 8 months.

The CDC's Advisory Committee on Immunization Practices also voted to include Enflonsia in the Vaccines for Children program, aimed at improving access for eligible infants, the company said.

Enflonsia is a long-acting monoclonal antibody designed to offer direct protection throughout a typical five-month respiratory syncytial virus season with a single weight-independent dose, it added.

The company said it expects to begin shipping the product ahead of the 2025-2026 RSV season, with availability for ordering starting in July.

The recommendation is provisional and will take effect once approved by the CDC Director or the Health and Human Services Secretary, according to the company.

Price: 79.22, Change: -0.45, Percent Change: -0.56